Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCRX NASDAQ:CLDX NASDAQ:RIGL NASDAQ:ZBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCRXBioCryst Pharmaceuticals$9.34-0.4%$9.22$6.00▼$11.22$2.38B0.554.70 million shs1.85 million shsCLDXCelldex Therapeutics$35.28-0.4%$33.64$19.72▼$40.30$2.78B0.91.21 million shs639,219 shsRIGLRigel Pharmaceuticals$36.74-0.2%$35.00$19.51▼$52.24$681.24M1.14383,112 shs485,198 shsZBIOZenas BioPharma$30.39-1.9%$22.97$13.50▼$44.60$1.96B-0.961.08 million shs558,940 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCRXBioCryst Pharmaceuticals-0.43%+0.54%-6.36%+4.47%+8.48%CLDXCelldex Therapeutics-0.40%-0.20%+4.44%+5.98%+47.80%RIGLRigel Pharmaceuticals-0.22%-9.37%+0.52%+21.29%+74.37%ZBIOZenas BioPharma-1.94%+2.91%+39.40%+67.07%+94.56%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCRXBioCryst Pharmaceuticals$9.34-0.4%$9.22$6.00▼$11.22$2.38B0.554.70 million shs1.85 million shsCLDXCelldex Therapeutics$35.28-0.4%$33.64$19.72▼$40.30$2.78B0.91.21 million shs639,219 shsRIGLRigel Pharmaceuticals$36.74-0.2%$35.00$19.51▼$52.24$681.24M1.14383,112 shs485,198 shsZBIOZenas BioPharma$30.39-1.9%$22.97$13.50▼$44.60$1.96B-0.961.08 million shs558,940 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCRXBioCryst Pharmaceuticals-0.43%+0.54%-6.36%+4.47%+8.48%CLDXCelldex Therapeutics-0.40%-0.20%+4.44%+5.98%+47.80%RIGLRigel Pharmaceuticals-0.22%-9.37%+0.52%+21.29%+74.37%ZBIOZenas BioPharma-1.94%+2.91%+39.40%+67.07%+94.56%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCRXBioCryst Pharmaceuticals 2.67Moderate Buy$20.80122.70% UpsideCLDXCelldex Therapeutics 2.86Moderate Buy$52.7749.57% UpsideRIGLRigel Pharmaceuticals 2.33Hold$54.5048.34% UpsideZBIOZenas BioPharma 2.56Moderate Buy$44.2945.72% UpsideCurrent Analyst Ratings BreakdownLatest RIGL, CLDX, BCRX, and ZBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/22/2026CLDXCelldex Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$54.00 ➝ $48.007/22/2026CLDXCelldex Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$44.00 ➝ $40.007/22/2026CLDXCelldex Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$67.00 ➝ $61.007/22/2026CLDXCelldex Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$62.00 ➝ $60.007/20/2026CLDXCelldex Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$90.00 ➝ $100.007/17/2026CLDXCelldex Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026RIGLRigel Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)7/13/2026BCRXBioCryst Pharmaceuticals JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$12.007/9/2026ZBIOZenas BioPharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)7/7/2026BCRXBioCryst Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$13.00 ➝ $14.006/30/2026BCRXBioCryst Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$32.00(Data available from 7/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCRXBioCryst Pharmaceuticals$874.84M2.71$1.23 per share7.58($0.57) per share-16.39CLDXCelldex Therapeutics$1.54M1,798.13N/AN/A$7.93 per share4.45RIGLRigel Pharmaceuticals$299.77M2.27$6.73 per share5.46$21.57 per share1.70ZBIOZenas BioPharma$10M191.85N/AN/A$4.51 per share6.74Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCRXBioCryst Pharmaceuticals$263.86M-$1.78N/A14.59N/A-51.71%-76.36%60.12%8/3/2026 (Estimated)CLDXCelldex Therapeutics-$258.76M-$4.26N/AN/AN/AN/A-50.72%-46.59%8/6/2026 (Estimated)RIGLRigel Pharmaceuticals$367.02M$18.721.969.75N/A121.50%47.99%32.40%8/4/2026 (Estimated)ZBIOZenas BioPharma-$377.74M-$8.47N/AN/AN/AN/A-99.99%-58.06%8/11/2026 (Estimated)Latest RIGL, CLDX, BCRX, and ZBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2026Q2 2026ZBIOZenas BioPharma-$0.89N/AN/AN/A$15.00 millionN/A8/6/2026Q2 2026CLDXCelldex Therapeutics-$1.04N/AN/AN/A$0.74 millionN/A8/4/2026Q2 2026RIGLRigel Pharmaceuticals$0.1377N/AN/AN/A$56.12 millionN/A8/3/2026Q2 2026BCRXBioCryst Pharmaceuticals$0.14N/AN/AN/A$183.28 millionN/A5/13/2026Q1 2026ZBIOZenas BioPharma-$1.4742-$1.46+$0.0142-$1.46$25.00 millionN/A5/7/2026Q1 2026CLDXCelldex Therapeutics-$1.1472-$1.18-$0.0328-$1.18$0.80 million$0.02 million5/6/2026Q1 2026BCRXBioCryst Pharmaceuticals$0.06-$2.98-$3.04-$2.98$151.12 million$156.41 million5/5/2026Q1 2026RIGLRigel Pharmaceuticals$0.7950$0.44-$0.3550$0.44$62.40 million$58.82 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBCRXBioCryst PharmaceuticalsN/AN/AN/AN/AN/ACLDXCelldex TherapeuticsN/AN/AN/AN/AN/ARIGLRigel PharmaceuticalsN/AN/AN/AN/AN/AZBIOZenas BioPharma$0.050.16%N/AN/A N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCRXBioCryst PharmaceuticalsN/A1.911.88CLDXCelldex TherapeuticsN/A8.928.92RIGLRigel Pharmaceuticals0.042.622.48ZBIOZenas BioPharma1.0411.9411.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCRXBioCryst Pharmaceuticals85.88%CLDXCelldex TherapeuticsN/ARIGLRigel Pharmaceuticals66.23%ZBIOZenas BioPharmaN/AInsider OwnershipCompanyInsider OwnershipBCRXBioCryst Pharmaceuticals3.80%CLDXCelldex Therapeutics5.20%RIGLRigel Pharmaceuticals10.47%ZBIOZenas BioPharma22.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCRXBioCryst Pharmaceuticals530254.16 million244.51 millionOptionableCLDXCelldex Therapeutics15078.49 million74.41 millionOptionableRIGLRigel Pharmaceuticals16018.50 million16.57 millionOptionableZBIOZenas BioPharmaN/A63.13 million49.24 millionN/ARIGL, CLDX, BCRX, and ZBIO HeadlinesRecent News About These Companies125,232 Shares in Zenas BioPharma, Inc. $ZBIO Bought by Walleye Capital LLCJuly 24 at 5:51 AM | marketbeat.comSEB Asset Management AB Invests $3.20 Million in Zenas BioPharma, Inc. $ZBIOJuly 24 at 4:57 AM | marketbeat.comJennison Associates LLC Buys Shares of 250,000 Zenas BioPharma, Inc. $ZBIOJuly 22 at 4:56 AM | marketbeat.comZenas BioPharma Grants Inducement Stock Options and RSUs to New EmployeesJuly 17, 2026 | quiverquant.comQZenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 17, 2026 | globenewswire.comZenas BioPharma (NASDAQ:ZBIO) Stock Price Up 7.2% - Time to Buy?July 17, 2026 | marketbeat.comZenas BioPharma: Obexelimab Could Build An Autoimmune FranchiseJuly 14, 2026 | seekingalpha.comZenas BioPharma (ZBIO): Best IPO Stocks with Huge Upside PotentialJuly 11, 2026 | finance.yahoo.comZenas BioPharma (NASDAQ:ZBIO) Trading Down 8% - Here's WhyJuly 10, 2026 | marketbeat.comZenas BioPharma Inc ZBIOJune 27, 2026 | morningstar.comMZenas BioPharma Announces Positive Phase 3 Obexelimab ResultsJune 24, 2026 | theglobeandmail.comZenas BioPharma's CEO Purchased 60,000 Company Shares. Here's a Deeper Look at the Transaction.June 21, 2026 | fool.comZenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 17, 2026 | globenewswire.comZenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert SummitJune 11, 2026 | globenewswire.comZenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR ...June 2, 2026 | finance.yahoo.comZenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of MedicineJune 2, 2026 | globenewswire.comA Look At Zenas BioPharma (ZBIO) Valuation After Strong 1-Year Return And Recent Share Price WeaknessJune 1, 2026 | finance.yahoo.comZenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RDMay 28, 2026 | globenewswire.comZenas Biopharma Inc.May 26, 2026 | money.usnews.comZenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 ...May 19, 2026 | markets.businessinsider.comZenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 CongressMay 19, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRIGL, CLDX, BCRX, and ZBIO Company DescriptionsBioCryst Pharmaceuticals NASDAQ:BCRX$9.34 -0.04 (-0.43%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$9.36 +0.02 (+0.24%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.Celldex Therapeutics NASDAQ:CLDX$35.28 -0.14 (-0.40%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$35.28 -0.01 (-0.01%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.Rigel Pharmaceuticals NASDAQ:RIGL$36.74 -0.08 (-0.22%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$36.65 -0.09 (-0.24%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.Zenas BioPharma NASDAQ:ZBIO$30.39 -0.60 (-1.94%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$30.76 +0.38 (+1.23%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Plugging In: How Kinder Morgan Powers Up Profits TSMC’s Price Hikes Could Show Which AI Chip Stocks Have Real Pricing Power AMD’s $5 Billion Anthropic Deal Could Redraw the AI Chip Battle Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
